PMID- 30796884
OWN - NLM
STAT- MEDLINE
DCOM- 20200504
LR  - 20200504
IS  - 2589-0646 (Electronic)
IS  - 2589-0646 (Linking)
VI  - 12
IP  - 3
DP  - 2019 Sep
TI  - Phenotypic characterization of malignant progenitor cells in patients with 
      idiopathic myelofibrosis.
PG  - 146-154
LID - S1658-3876(19)30002-0 [pii]
LID - 10.1016/j.hemonc.2019.01.001 [doi]
AB  - OBJECTIVE/BACKGROUND: Idiopathic myelofibrosis (IM) is a clonal hematological 
      malignancy originating from pluripotent hematopoietic stem cells (HSC). HSC are 
      very rare potent cells that reside in the bone marrow (BM) and at a lower level 
      in peripheral blood (PB). Previous studies showed that IM PB CD34(+) cells 
      contain not only BM repopulating cells belonging to the malignant clone but also 
      residual normal HSC. METHODS: In the current study, we separated the 
      subpopulations of IM PB CD34(+) cells using IL-3Ralpha/CD123 labeling and further 
      characterized them by genetic and functional analyses. RESULTS: We differentiated 
      IM PB CD34(+) cells into three subpopulations (IL-3Ralpha(high), IL-3Ralpha(low), and 
      IL-3Ralpha(negative)). IL-3Ralpha(high) CD34(+) cell subgroup represents a small 
      population in IM PB CD34(+) cells which was not seen in normal G-CSF mobilized 
      CD34(+) cells. IM IL-3Ralpha(high) CD34(+) cells contained significant higher 
      percentage of cells bearing marker chromosome detected by fluorescence in situ 
      hybridization (FISH) analysis. In the absence of growth factors, IM IL-3Ralpha(high) 
      CD34(+) cells exhibited abnormal colony forming ability and carried greater 
      percentage of JAK2V617F mutant allele compared with IL-3Ralpha(low) and 
      IL-3Ralpha(negative) CD34(+) cells. CONCLUSION: These data indicate that IL-3Ralpha(high) 
      CD34(+) cells from IM enriched for the malignant progenitor cells and 
      IL-3Ralpha/CD123 may be a potential biomarker and therapeutic target for IM. Our 
      findings will be further validated in future studies with a larger sample size 
      and serial transplant in murine models.
CI  - Copyright (c) 2019 King Faisal Specialist Hospital & Research Centre. Published by 
      Elsevier Ltd. All rights reserved.
FAU - Bao, Yonghua
AU  - Bao Y
AD  - Department of Pathology, Institute of Precision Medicine, Jining Medical 
      University, Jining, China. Electronic address: baoyonghua2005@126.com.
FAU - Hu, Wenyang
AU  - Hu W
AD  - Department of Pathology, Institute of Precision Medicine, Jining Medical 
      University, Jining, China. Electronic address: wyhu02@yahoo.com.
FAU - Guo, Yongchen
AU  - Guo Y
AD  - Department of Pathology, Institute of Precision Medicine, Jining Medical 
      University, Jining, China.
FAU - Yang, Wancai
AU  - Yang W
AD  - Department of Pathology, Institute of Precision Medicine, Jining Medical 
      University, Jining, China.
LA  - eng
PT  - Journal Article
DEP - 20190220
PL  - Saudi Arabia
TA  - Hematol Oncol Stem Cell Ther
JT  - Hematology/oncology and stem cell therapy
JID - 101468532
RN  - 0 (Antigens, CD34)
RN  - 0 (IL3RA protein, human)
RN  - 0 (Interleukin-3 Receptor alpha Subunit)
RN  - EC 2.7.10.2 (JAK2 protein, human)
RN  - EC 2.7.10.2 (Janus Kinase 2)
SB  - IM
MH  - Antigens, CD34/analysis/genetics
MH  - Cells, Cultured
MH  - Chromosome Aberrations
MH  - Hematopoietic Stem Cells/metabolism/*pathology
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Interleukin-3 Receptor alpha Subunit/analysis/genetics
MH  - Janus Kinase 2/genetics
MH  - Neoplastic Stem Cells/metabolism/pathology
MH  - Point Mutation
MH  - Primary Myelofibrosis/genetics/*pathology
OTO - NOTNLM
OT  - Chromosome abnormality
OT  - IL3-Ralpha
OT  - Idiopathic myelofibrosis
OT  - JAK2V617F
EDAT- 2019/02/24 06:00
MHDA- 2020/05/05 06:00
CRDT- 2019/02/24 06:00
PHST- 2018/08/16 00:00 [received]
PHST- 2019/01/07 00:00 [revised]
PHST- 2019/01/21 00:00 [accepted]
PHST- 2019/02/24 06:00 [pubmed]
PHST- 2020/05/05 06:00 [medline]
PHST- 2019/02/24 06:00 [entrez]
AID - S1658-3876(19)30002-0 [pii]
AID - 10.1016/j.hemonc.2019.01.001 [doi]
PST - ppublish
SO  - Hematol Oncol Stem Cell Ther. 2019 Sep;12(3):146-154. doi: 
      10.1016/j.hemonc.2019.01.001. Epub 2019 Feb 20.